Newsfiscal.ai
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
· Published
Article summary
Immuneering Corporation presented the design and methodology of its Phase 3 MAPKeeper 301 clinical trial at the ESMO Congress 2026.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…